OphRx engages in the development of drugs for treating eye diseases using an innovative technological platform that enhances the transmission of active substances based on nanostructures.
For development and commercial reasons, OphRx has chosen to initially focus on a substance known as Cyclosporine with a high dosage of 0.5% compared with dosages currently available on the market of 0.05%-0.09% (for example Restasis by Allergan). These products are currently used to treat DES patients but encounter significant barriers to adaptation by patients due to a burning sensation on contact, and slow and limited symptom relief. According to market research studies and OphRx’s estimation, the market for these products exceeds $1.5 billion annually.
The company and OphRx believe that the OphRx technology could serve as a platform for different uses in the field of eye medication administration, including in connection with diseases of the front of the eye and/or diseases of the back of the eye, and therefore OphRx is focused on the development of medications for various diseases.